Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), bought 85,000 shares at $111.56 ($9.4M) on 2020-05-27, disclosed to the SEC on 2020-05-27.
Open-market purchase of $9.4M JAZZ by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $110.65 | 15,000 | $1.7M | 17.6% |
| 2 | $109.55 | 5,243 | $574K | 6.1% |
| 3 | $109.55 | 5,243 | $574K | 6.1% |
| 4 | $110.52 | 8,391 | $927K | 9.8% |
| 5 | $110.52 | 8,391 | $927K | 9.8% |
| 6 | $111.56 | 9,884 |
| $1.1M |
| 11.7% |
| 7 | $111.56 | 9,884 | $1.1M | 11.7% |
| 8 | $112.32 | 11,482 | $1.3M | 13.7% |
| 9 | $112.32 | 11,482 | $1.3M | 13.7% |
| Total | $111.15 avg | 85,000 | $9.4M | 100% |
| Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |
| JAZZ | SELL | 2016-02-24 | $6.9M | — | Filing → |